Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Sarcopenia-driven brain and muscle creatine deficit could be seen as a distinctive pathological facet of this condition, and this might be approached with targeted therapies in aim to restore creatine homeostasis in target tissues. Among potential therapeutic candidates, guanidinoacetate (GAA) appears recently as a direct precursor of creatine that may favorably upregulate muscle and brain creatine concentration. Interestingly, GAA-creatine mixture was found to be superior than creatine itself to effectively improves bioenergetics in the human brain and muscle in healthy humans, perhaps due to the unique transportability features of this combination. Here, we plan to evaluate does creatine-GAA supplementation affects various biomarkers of sarcopenia in elderly.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Creatine-guanidinoacetic acid | Experimental | 2 grams of creatine and 2 grams of GAA Administered one dose two times per day on an empty stomach in the morning and at the evening |
|
| Inulin | Placebo Comparator | 4 grams of inulin Administered one dose two times per day on an empty stomach in the morning and at the evening |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Creatine-guanidinoacetic acid | Dietary Supplement | A dietary supplement provided as powder dissolved in a glass of water |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in muscular strength | Baseline vs. 6 months | Baseline vs. 6 months post-intervention |
| Measure | Description | Time Frame |
|---|---|---|
| Change in muscle mass | Baseline vs. 6 months | Baseline vs. 6 months post-intervention |
| Change in muscle metabolites evaluated with MR spectroscopy | Baseline vs. 6 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Applied Bioenergetics Lab at Faculty of Sport and PE | Novi Sad | Vojvodina | 21000 | Serbia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D055948 | Sarcopenia |
| ID | Term |
|---|---|
| D009133 | Muscular Atrophy |
| D020879 | Neuromuscular Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D007444 | Inulin |
| ID | Term |
|---|---|
| D013213 | Starch |
| D005936 | Glucans |
| D001704 | Biopolymers |
| D011108 | Polymers |
| D046911 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Inulin | Other | A dietary supplement provided as powder dissolved in a glass of water |
|
| Baseline vs. 6 months post-intervention |
| Change in cognitive performance evaluated with Mini-Mental State Exam test | Baseline vs. 6 months | Baseline vs. 6 months post-intervention |
| Change in serum creatine | Baseline vs. 6 months | Baseline vs. 6 months post-intervention |
| D001284 | Atrophy |
| D020763 | Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012816 | Signs and Symptoms |
| Macromolecular Substances |
| D004040 | Dietary Carbohydrates |
| D002241 | Carbohydrates |
| D005630 | Fructans |
| D011134 | Polysaccharides |